Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8401-8410 Newer>

Chemistry World August 23, 2012 Dean Baker	Monopoly money It is remarkable that the system of patent support for prescription drug research has not become more of a policy issue.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Chemistry World August 20, 2012	Generic Actos Approved Three generics manufacturers - Mylan, Ranbaxy and Teva - have won US marketing approval for their generic versions of Actos diabetes tablets.
Chemistry World August 20, 2012	Pads Pick up Counterfeit Drugs Different lanes on the Pad test for different chemical characteristics of both active and supplementary ingredients in drugs.
Pharmaceutical Executive August 1, 2012	Country Report: Mexico Jim O'Neill, chief economist at Goldman Sachs declared that by 2020 Mexico would be the seventh largest economy in the world, surpassing both India and Russia. The Mexican pharmaceutical industry has seen some significant changes over the last four years.
Chemistry World August 17, 2012 Andrew Turley	Pfizer to pay $250m for Nexium Pfizer has struck a $250 million deal with UK rival AstraZeneca to sell an over-the-counter version of Nexium (esomeprazole magnesium) heartburn tablets.
Chemistry World August 14, 2012 Andrew Turley	Elan spins off drug discovery Irish drug maker Elan is to spin off its drug discovery activities as an independent company of 80 employees -- just under half the Elan workforce -- called Neotope Biosciences. The new company will focus on chronic degenerative diseases.
Pharmaceutical Executive August 1, 2012 Pascheles & Bogan	The Ultimate Business Model: Planning that Thousand Year Future In an era where success is monitored and measured in microseconds, planning for the long term is increasingly seen as an abstract absurdity. Yet the principles of natural selection, when applied to the pharmaceutical business, suggest that a lasting business model is still possible.
Pharmaceutical Executive August 1, 2012	Piramal Pivots for Growth Western drug makers face an unlikely challenge from India's Piramal Healthcare, which has divested its big stake in branded generics for the risky embrace of new drug innovation.
Pharmaceutical Executive August 1, 2012 Ben Comer	Compliance Kulture: The Facts Behind GSK's CIA Big Pharma talks a lot about changing its business model to one that prioritizes quality and value over quantity and waste. How do you judge a sales rep's performance if not on how much she sells?
<Older 8401-8410 Newer> Return to current articles.